References:
  1. Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis. J Allergy Clin Immunol 2013;131(1):144-149.
  2. Laroche D, Dubois F, Gérard JL et al. Radioimmunoassay for plasma histamine: a study of false positive and false negative values. Br J Anaesth 1995;74(4):430-437.
  3. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1977;309(8009):466-469.
  4. Valent P, Akin C, Arock M et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012;157:215–225.
  5. Sarrat A, Couderc R, Alyanakian MA et al. Performance criteria for the verification of IgE and tryptase assay methods: recommendations from the AllergoBioNet network. Ann Biol Clin 2020;78(3):329-342. (French )
  6. Poli C, Laurichesse M, Rostan O et al. Comparison of two enzymatic immunoassays, high resolution mass spectrometry method and radioimmunoassay for the quantification of human plasma histamine. J Pharm Biomed Anal 2016;118:307-314.
  7. Laroche D, Debaene B. How to relate the observed event to anaphylaxis? Practice of diagnostic investigations. Ann Fr Anesth Reanim 2011;30(3):280-293. (French )
  8. Thermo Fisher diagnostics. ImmunoCAP TM Tryptase - Phadia. Fluoroenzymeimmunoassay. Directions for Use 52-5467-EN/03.
  9. Laroche D, Mayo P, Lefrancois C et al. Exploration in vitro de l’anaphylaxie médicamenteuse. Immunoanal Biol Spec.1998;13(2):63-73.